Search

41 Result(s)
Sort by

AMR_Action_Fund

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Our Partners Bioharmony

Our Partners Bioharmony

Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
More Green Overview

More Green Overview

Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
ATM-Ranking-2021

ATM-Ranking-2021

Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
Keep water clean

Keep water clean

Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.
Aptivus®

Aptivus®

Indicated for combination antiretroviral treatment of HIV-1-infected patients, co-administered with 200 mg of ritonavir, who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.
TCO patient podcasts

TCO patient podcasts

From clinical trials to living with cancer, hear patient perspectives on different cancer topics in this podcast series.
Ruminant parasite control in a nutshell

Ruminant parasite control in a nutshell

An exclusive drug-based approach to fight worms is dying. Dr. Ray Kaplan, from Georgia University, explains five things you need to know.